Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akso Health GroupAHG -0.63%36 EV-to-EBIT is -336.30 as of Aug. 01, 2026. GuruFocus rates AHG with a GF Score™ of 36/100 and a GF Value™ of $0.40 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 94 Medical Distribution companies, Akso Health Group ranks worse than 1063828.72% on this metric.
Akso Health Group (NAS:AHG) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Akso Health Group's Enterprise Value for the quarter that ended in Mar. 2026 was $1,953.48 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Akso Health Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akso Health Group EV-to-EBIT Related Terms
Akso Health Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Akso Health Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Akso Health Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akso Health Group EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Akso Health Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Akso Health Group's EV-to-EBIT falls into.
Akso Health Group's current Enterprise Value is $1,345.22 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Akso Health Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akso Health Group (AHG) has a EV-to-EBIT of -336.30 as of Aug. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Akso Health Group and its competitors. According to the industry distribution chart, Akso Health Group ranks #999999 out of 94 companies in the Medical Distribution industry.
Is Akso Health Group's EV-to-EBIT too high?
Akso Health Group's current EV-to-EBIT is -336.30. Based on the distribution chart, Akso Health Group ranks #999999 out of 94 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Akso Health Group has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Akso Health Group's EV-to-EBIT compare to ACH and FOCL?
According to the Medical Distribution industry distribution chart, Akso Health Group ranks #999999 out of 94 companies for EV-to-EBIT. This places Akso Health Group in the lower half of its industry. The industry median EV-to-EBIT is 11.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.71, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Akso Health Group and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akso Health Group's current EV-to-EBIT is -336.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akso Health Group stock overvalued right now?
Based on GuruFocus' analysis, Akso Health Group (AHG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.40, compared to a current price of $1.57 — trading 292.5% above its estimated fair value. The current EV-to-EBIT is -336.30. Akso Health Group's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Akso Health Group (AHG), the current EV-to-EBIT is -336.30 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akso Health Group (AHG) Overvalued in 2026?
Based on GuruFocus' analysis, Akso Health Group stock appears to be overvalued.
The current stock price of $1.57 is trading 292.5% above its estimated GF Value™ of $0.40.
GuruFocus considers Akso Health Group to be Significantly Overvalued.
Key valuation signals for AHG:
EV-to-EBIT: -336.30
GF Value™: $0.40 vs. price of $1.57 (292.5% above fair value)
No single metric tells the full story. See the AHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
36GF Score
Get the complete analysis for AHG
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AHG has been successfully added to your 
